Company intelligence / Profile preview
Kantify
Brussels, Belgiumkantify.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Kantify has demonstrated the ability of its AI platform, Sapian, to rapidly identify and validate first-in-class drug candidates for hard-to-treat conditions, with published preclinical results such as inhibition of tumor growth in prostate cancer models and discovery of novel ion channel activators[1][2].
- Therapeutic areas
- CardiovascularOncologyNeurology
- Modalities
- Small moleculeTargeted protein degrader
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Johns Hopkins School of MedicineInstitut du Thorax (Nantes)AFM-TéléthonEuropean Union (EU funding through Project James)
Beyond the preview
Go deeper on Kantify.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kantify.